Esra FIRAT, Abdulsamet ERDEN, Berkan ARMAĞAN, Levent KILIÇ, Şule APRAŞ BİLGEN, Alper SARI, Umut KALYONCU, Sedat KİRAZ, Ömer KARADAĞ, Gözde Kübra YARDIMCI, İhsan ERTENLİ, Ali AKDOĞAN

Anti-interleukin-6 (tocilizumab) therapy in Takayasu’s arteritis: a real life experience

Background/aim: Tumour necrosis factor inhibitors and anti-interleukin-6 (anti-IL-6) therapies are increasingly being used inTakayasu’s arteritis (TA) patients who are unresponsive to corticosteroids ± conventional immunosuppressive agents. The aim of thisstudy is to assess the efficacy and safety of anti-IL-6 (tocilizumab) therapy in refractory TA patients in real life.Materials and methods: Fifteen TA patients (86.7% were female) who received at least 3 cycles of tocilizumab therapy were retrospectivelyassessed by clinical, laboratory, and radiological evaluations before and after tocilizumab therapy.Results: The median (min–max) age of the patients at evaluation was 35 (20–58) years and the median disease duration from diagnosiswas 24 (12–168) months. The median (min.–max.) duration of follow-up after tocilizumab was 15 (3–42) months. There was a significantdecrease in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and patient global visual analogue scale (VAS) scores ofpatients after tocilizumab therapy. The median (min.–max.) ESR was 26 (5–119) vs. 3 (2–49) mm/h, P = 0.02; CRP was 39.8 (2.4–149.0)vs. 7.9 (0–92.9) mg/L, P = 0.017; and patient global VAS was 50 (0–90) vs. 30 (0–60), P = 0.027, respectively. In 8 patients, ESR and CRPlevels were in the normal range in the last control. Imaging modality results after tocilizumab were available for 9 patients; 8 patientswere radiologically stable and regression was seen in 1 patient. Comparable imaging modality results before and after tocilizumab wereavailable for 5 patients; 4 patients were radiologically stable and regression was seen in 1 patient. Radiological findings were consistentwith laboratory responses. Glucocorticoid dosages decreased from a mean dosage of 16.2 (9.1) mg/day at baseline to 7.1 (3.8) mg/day (P= 0.001) at the last follow-up visit. There was no increase in the steroid dosage in any of the patients. All patients tolerated tocilizumabwell.Conclusion: Based on retrospective real life data, anti-IL-6 (tocilizumab) appears to be an effective and tolerable treatment option inrefractory TA patients.

PDF

___

1. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. International Journal of Cardiology 1996; 54 (Suppl.): S155-163.
2. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. Journal of Clinical Pathology 2002; 55 (7): 481-486. doi: 10.1136/jcp.55.7.481
3. Kotter I, Henes JC, Wagner AD, Loock J, Gross WL. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clinical and Experimental Rheumatology 2012; 30 (1 Suppl. 70): S114-129.
4. Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Current Opinion in Rheumatology 2014; 26 (1): 7-15. doi: 10.1097/BOR.0000000000000004
5. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmunity Reviews 2011; 11 (1): 61-67. doi: 10.1016/j. autrev.2011.08.001
6. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford, England) 2006; 45 (5): 545-548. doi: 10.1093/rheumatology/kei266
7. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology 2006; 2 (11): 619-626. doi: 10.1038/ncprheum0338
8. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford, England) 2012; 51 (1): 151- 156. doi: 10.1093/rheumatology/ker296
9. Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clinical and Experimental Rheumatology 2012; 30 (1 Suppl. 70): S90-93.
10. Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmunity Reviews 2013; 12 (12): 1143-1149. doi: 10.1016/j.autrev.2013.06.019
11. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. International Journal of Rheumatic Diseases 2013; 16 (6): 754-761. doi: 10.1111/1756-185X.12220
12. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. Journal of Rheumatology 2013; 40 (12): 2047-2051. doi: 10.3899/ jrheum.130536
13. Canas CA, Canas F, Izquierdo JH, Echeverri AF, Mejia M et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 2014; 20 (3): 125- 129. doi: 10.1097/RHU.0000000000000098
14. Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE et al. Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation 2015; 132 (18): 1693-1700. doi: 10.1161/ CIRCULATIONAHA.114.014321
15. Batu ED, Sönmez HE, Hazırolan T, Özaltın F, Bilginer Y et al. Tocilizumab treatment in childhood Takayasu arteritis: case series of four patients and systematic review of the literature. Seminars in Arthritis and Rheumatism 2017; 46 (4): 529-535. doi: 10.1016/j.semarthrit.2016.07.012
16. Nakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. International Heart Journal 2013; 54 (6): 405-411. doi: 10.1536/ihj.54.405
17. Decker P, Olivier P, Risse J, Zuily S, Wahl D. Tocilizumab and refractory Takayasu disease: Four case reports and systematic review. Autoimmunity Reviews 2018; 17 (4): 353-360. doi: 10.1016/j.autrev.2017.11.026
18. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebocontrolled, phase 3 trial in Japan (the TAKT study). Annals of the Rheumatic Diseases 2018; 77 (3): 348-354. doi: 10.1136/ annrheumdis-2017-211878
19. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS et al. Takayasu arteritis. Annals of Internal Medicine 1994; 120 (11): 919-929.
20. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clinical and Experimental Rheumatology 2003; 21 (6 Suppl. 32): S23-28.